The Importance of Molecular Testing for the Diagnosis of Fabry Disease Manifested by Cornea Verticillata Only
Ophthalmology Research: An International Journal,
Aims: To describe a Fabry disease, that it’s diagnosis was only possible through the molecular test
Presentation of Case: L.A.P. female, 42 years old, lawyer, seen by the ophthalmology department for routine consultation only with refractive complaints. Fundus of the eye: Mild narrowing with increased vascular brightness and presence of pathological arteriovenous crossings. The rest of the exam was within normal limits.
Therefore, a genetic test with the dosage of the α-Gal enzyme was requested, which evidenced the alteration in it, confirming the diagnosis of Fabry disease.
Discussion: A Fabry Disease (FD) is an inborn error of glycosphingolipid (GL) metabolism, resulting from deficient activity of the enzyme alpha-galactosidase A (α -Gal). It has X-chromosome-linked inheritance, affecting mainly males, with an estimated prevalence of 1:40,000 males. The expression of the disease in heterozygous female patients can vary from an asymptomatic condition to a severe systemic disease, like that which occurs in men.
Conclusions: The ophthalmological examination played an important role in the diagnosis, as this change is highly suggestive of the disease, in order to avoid erroneous and late diagnoses that can cause consequences for patients with this condition.
- Fabry disease
- genetic error
- verticillate cornea
How to Cite
Davey PG. Fabry disease: a survey of visual and ocular symptoms. Clin Ophthalmol. 2014;8: 1555 – 1560.
Eng CM, Fletcher J, Wilcox WR et al. Fabry Disease: Baseline medical characteristics of a cohort of 1765 men and women in the Fabry Registry. J Inherit Metab Dis. 2007;30:184 –192.
Falke K , Büttner A , Schittkowski M , Stachs O , Kraak R , Zhivov A , Rolfs A & Guthoff R. The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal study of microscopy of laser scanning. Graefes Arch Clin Exp Ophthalmol 22009;47: 523 - 534.
Fledelius HC , Sandfeld L , Rasmussen ÅK, Madsen CV and Feldt-Rasmussen U. Ophthalmic experience of more than 10 years in a Danish observational cohort of Fabry patients with access to enzyme replacement. Acta Ophthalmol. 2015;93: 258 -264.
Franssen L, Coppens JE & van den Berg TJ. Compensation comparison method for retinal scattered light assessment. Invest Ophthalmol Vis Sci. 2006;47:768- 776.
Hiraoka T, Okamoto C, Ishii Y, Kakita T & Oshika T. Contrast sensitivity function and higher order ocular aberrations after overnight orthokeratology. Invest Ophthalmol Vis Sci. 2007;48:550 – 556.
Hiraoka T, Daito M, Okamoto F, Kiuchi T & Oshika T. Contrast sensitivity and optical quality of the eye after instillation of timolol maleate gel forming solution and brinzolamide ophthalmic suspension. Ophthalmology.2010;117: 2080- 2087.
Koh S , Hamano T , Sakai N , Maeda N & Nishida K. Impaired visual function associated with cornea verticilata due to Fabry disease. J Intern Med. 2017;47:969 - 971.
Koh S, Sakai N, Maeda N & Nishida K. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy. Acta Ophthalmol. 2018;96: 255 - 256.
Mehta A, Ricci R, Widmer U et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236 - 242.
Orssaud C , Dufier J & Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygotic male patients. Ophthalmic Genet. 2003;24:129- 139.
Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, Beck M, Gal A. Eye signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE. 2015;10:e0120814.
Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, Ulrich RG. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62:286-301.
Shimizu E, Yamaguchi T, Yagi-Yaguchi Y, Dogru M, Satake Y, Tsubota K and Shimazaki J. Higher order corneal aberrations in infectious keratitis. Am J Ophthalmol. 2017;175:148-158.
Sivley MD. Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci 2013;90: e63 - e78.
Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. ocular manifestations of Fabry disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91:210 - 214.
van der Tol L, Sminia ML, Hollak CE and Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016;100:3 - 8.
Yamaguchi T, Shimizu E, Yagi-Yaguchi Y, Tomida D, Satake Y & Shimazaki JA. New corneal disease entity with irregular posterior corneal surfaces: concept and clinical relevance. Cornea. 2017;36 (Supplement 1):S53 - S59.
Abstract View: 147 times
PDF Download: 44 times